ArticleOphthalmology and therapy2026
Efficacy and Safety Outcomes of Fluocinolone Acetonide Intravitreal Implant in Refractory Diabetic Macular Edema: A Real-World Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to evaluate the long-term efficacy and safety of the 0.19 mg fluocinolone acetonide (FAc) intravitreal implant in patients with refractory diabetic macular edema (DME).
methodsIn this retrospective single-center study, patients with refractory DME treated with the 0.19 mg FAc implant (Iluvien
resultsIn total, 49 eyes from 39 patients (mean age 70.4 ± 9.8 years) were analyzed. All eyes had previously received anti-vascular endothelial growth factor (anti-VEGF) agents and/or short-acting intravitreal corticosteroids, and 47 (95.9%) had undergone laser photocoagulation. Mean follow-up was 23.9 ± 11.4 months. Mean CRT decreased from 502.1 ± 154.0 µm to 325.6 ± 102.9 µm (mean change -176.5 ± 114.8 µm; p < 0.0001). CRT reductions ≥ 20% and ≥ 30% occurred in 87.8% and 49.0% of eyes, respectively, and 55.1% achieved CRT ≤ 300 µm. Mean BCVA improved from 47.3 ± 18.2 to 54.9 ± 14.7 letters (mean gain 7.6 ± 11.2 letters; p < 0.0001). Transient intraocular pressure (IOP) elevation occurred in 38.8% of eyes, with one case requiring surgery. Additional DME treatment was required in 26.5% of eyes.
conclusionsThese findings suggest that the FAc implant provides sustained anatomical and visual benefits with a manageable safety profile in chronic refractory DME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.